Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

466 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.
Iurlo A, Cattaneo D, Consonni D, Castagnetti F, Miggiano MC, Binotto G, Bonifacio M, Rege-Cambrin G, Tiribelli M, Lunghi F, Gozzini A, Pregno P, Abruzzese E, Capodanno I, Bucelli C, Pizzuti M, Artuso S, Iezza M, Scalzulli E, La Barba G, Maggi A, Russo S, Elena C, Scortechini AR, Tafuri A, Latagliata R, Caocci G, Bocchia M, Galimberti S, Luciano L, Fava C, Foà R, Saglio G, Rosti G, Breccia M. Iurlo A, et al. Among authors: galimberti s. Front Pharmacol. 2023 Mar 23;14:1154377. doi: 10.3389/fphar.2023.1154377. eCollection 2023. Front Pharmacol. 2023. PMID: 37033642 Free PMC article.
Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.
Bucelli C, Capodanno I, Miggiano MC, Cavazzini F, Crescenzi SL, Russo S, Carmosino I, Annunziata M, Sorà F, Bonifacio M, Luciano L, Caocci G, Loglisci G, Elena C, Lunghi F, Mullai R, Attolico I, Binotto G, Crisà E, Sportoletti P, Di Veroli A, Scortechini AR, Leporace AP, Maggi A, Crugnola M, Stagno F, Sancetta R, Murgano P, Rapezzi D, Luzi D, Vincelli DI, Galimberti S, Bocchia M, Fava C, Malato A, Abruzzese E, Saglio G, Specchia G, Breccia M, Iurlo A, Tiribelli M, Latagliata R. Bucelli C, et al. Among authors: galimberti s. Eur J Haematol. 2025 Jan;114(1):37-44. doi: 10.1111/ejh.14299. Epub 2024 Sep 12. Eur J Haematol. 2025. PMID: 39263855 Free PMC article.
Spatially Resolved Molecular Characterization of Noninvasive Follicular Thyroid Neoplasms with Papillary-like Nuclear Features (NIFTPs) Identifies a Distinct Proteomic Signature Associated with RAS-Mutant Lesions.
Denti V, Greco A, Alviano AM, Capitoli G, Monza N, Smith A, Pilla D, Maggioni A, Ivanova M, Venetis K, Maffini F, Garancini M, Pincelli AI, Galimberti S, Magni F, Fusco N, L'Imperio V, Pagni F. Denti V, et al. Among authors: galimberti s. Int J Mol Sci. 2024 Dec 6;25(23):13115. doi: 10.3390/ijms252313115. Int J Mol Sci. 2024. PMID: 39684824 Free PMC article.
Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions.
Ghelli Luserna di Rorà A, Jandoubi M, Padella A, Ferrari A, Marranci A, Mazzotti C, Olimpico F, Ghetti M, Ledda L, Bochicchio MT, Paganelli M, Zanoni M, Cafaro A, Servili C, Galimberti S, Gottardi M, Rondoni M, Endri M, Onofrillo D, Audisio E, Marconi G, Simonetti G, Martinelli G. Ghelli Luserna di Rorà A, et al. Among authors: galimberti s. J Transl Med. 2024 Nov 26;22(1):1062. doi: 10.1186/s12967-024-05838-9. J Transl Med. 2024. PMID: 39587643 Free PMC article.
Multi-year enzyme expression in patients with mucopolysaccharidosis type VI after liver-directed gene therapy.
Rossi A, Romano R, Fecarotta S, Dell'Anno M, Pecorella V, Passeggio R, Zancan S, Parenti G, Santamaria F, Borgia F, Deodato F, Funghini S, Rupar CA, Prasad C, O'Callaghan M, Mitchell JJ, Valsecchi MG, la Marca G, Galimberti S, Auricchio A, Brunetti-Pierri N. Rossi A, et al. Among authors: galimberti s. Med. 2024 Nov 12:S2666-6340(24)00419-7. doi: 10.1016/j.medj.2024.10.021. Online ahead of print. Med. 2024. PMID: 39547230
Long-term real world evidence of CPX-351 of high-risk AML patients identified high rate of negative MRD and prolonged OS.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahmé R, Bertoli S, Fianchi L, Micol JB, Gottardi M, Peterlin P, Galimberti S, Thomas X, Rizzuto G, Legrand O, Rondoni M, Raffoux E, Bertani G, Caulier AL, Dargenio M, Bonmati C, Billio A, Lejeune C, Scappini B, Pigneux A, Zappasodi P, Récher C, Grimaldi F, Adès L, Lemoli RM. Cluzeau T, et al. Among authors: galimberti s. Blood Adv. 2024 Oct 25:bloodadvances.2024014279. doi: 10.1182/bloodadvances.2024014279. Online ahead of print. Blood Adv. 2024. PMID: 39454204
Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy.
Mosna F, Borlenghi E, Litzow M, Byrd JC, Papayannidis C, Tecchio C, Ferrara F, Marcucci G, Cairoli R, Morgan EA, Gurrieri C, Yeung CCS, Deeg HJ, Capelli D, Candoni A, Gotlib JR, Lunghi M, Pullarkat S, Lanza F, Galimberti S, Forghieri F, Venditti A, Festuccia M, Audisio E, Marvalle D, Rigolin GM, Roti G, DiBona E, Visani G, Albano F, Eisfeld AK, Valent P, Huls G, Borthakur G, Krampera M, Martinelli G, Kröger N, Sperotto A, Gottardi M. Mosna F, et al. Among authors: galimberti s. Haematologica. 2024 Oct 10. doi: 10.3324/haematol.2024.285448. Online ahead of print. Haematologica. 2024. PMID: 39385741 Free article.
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network.
Breccia M, Cucci R, Marsili G, Castagnetti F, Galimberti S, Izzo B, Sorà F, Soverini S, Messina M, Piciocchi A, Bonifacio M, Cilloni D, Iurlo A, Martinelli G, Rosti G, Stagno F, Fazi P, Vignetti M, Pane F. Breccia M, et al. Among authors: galimberti s. Clin Lymphoma Myeloma Leuk. 2024 Sep 7:S2152-2650(24)01802-0. doi: 10.1016/j.clml.2024.08.009. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39322541
466 results